Grants.govNational Institutes of Health

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

Posted Nov 18, 2024·open

AGENCY

HHS-NIH11

PROGRAM

Discretionary

AMOUNT

—

CLOSES

Jan 7, 2027

Apply on Grants.gov ↗More info from funder ↗

Description

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Eligibility

Private institutions of higher education; Small businesses; For profit organizations other than small businesses; Native American tribal governments (Federally recognized); Special district governments; Public and State controlled institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); City or township governments; State governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Public housing authorities/Indian housing authorities; County governments

Contact

National Institutes of Health

grantsinfo@nih.gov

301-402-2541

Additional details

Funding instrument: Grant
Cost sharing required: No
Archived: Feb 12, 2027

Opportunity number: PAR-25-070

Search this number on Grants.gov for the official listing.